65岁以下重度主动脉瓣病变患者的管理挑战:综述
本综述聚焦65岁以下成人重度主动脉瓣病变(主动脉瓣狭窄与反流)的管理复杂性。文章指出机械瓣需终身抗凝、生物瓣存在结构衰败与再干预风险,Ross手术有前景但限于高度专业化中心,瓣膜修复适用于部分反流患者。强调多学科心脏团队与患者共同决策以权衡干预时机与各方案利弊。
要点
- 机械瓣主动脉瓣置换需终身抗凝,生物瓣存在结构衰败与后续再干预风险。
- 年轻患者尤其是考虑妊娠者,抗凝与瓣膜耐久性问题更为突出。
- Ross手术有前景但仅限高度专业化中心,瓣膜修复适用于部分主动脉瓣反流患者。
核心结论
- 65岁以下成人重度主动脉瓣病变管理复杂,每项决策均需多重考量。
- 机械瓣与生物瓣主动脉瓣置换历来是标准治疗,其他选择仅适用于部分患者且尚不能在专业化手术中心之外推广。
- 多学科心脏团队与患者的详细讨论是共享决策过程不可或缺的部分。
研究设计与样本
- 本文为综述,聚焦65岁以下成人重度主动脉瓣病变(主动脉瓣狭窄与主动脉瓣反流)的管理。
主要发现
- 机械瓣主动脉瓣置换患者需终身抗凝。
- 生物瓣主动脉瓣置换患者存在结构瓣膜衰败风险及需要后续瓣膜干预。
- 上述因素在考虑妊娠的年轻成人中更为突出,抗凝与瓣膜耐久性问题加剧。
- Ross手术已成为有前景的替代方案,但其应用仅限于高度专业化中心。
- 瓣膜修复是部分主动脉瓣反流患者的选择。
临床怎么用
- 由多学科瓣膜团队提供以患者为中心的照护,讨论最佳干预时机及各治疗方案的优缺点。
- 与患者进行详细讨论是共享决策过程的组成部分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The management of aortic valve disease, including aortic stenosis and aortic regurgitation (AR), in younger adult patients (age <65 years) is complex, and the optimal strategy is often unclear, contingent on multiple anatomic and holistic factors. OBSERVATIONS: Traditional surgical approaches carry significant considerations, including compulsory lifelong anticoagulation for patients who receive a mechanical aortic valve replacement (AVR) and the risk of structural valvular deterioration and need for subsequent valve intervention in those who receive a bioprosthetic AVR. These factors are magnified in young adults who are considering pregnancy, for whom issues of anticoagulation and valve longevity are heightened. The Ross procedure has emerged as a promising alternative; however, its adoption is limited to highly specialized centers. Valve repair is an option for selected patients with AR. These treatment options offer varying degrees of durability and are associated with different risks and complications, especially for younger adult patients. Patient-centered care from a multidisciplinary valve team allows for discussion of the optimal timing of intervention and the advantages and disadvantages of the various treatment options. CONCLUSIONS AND RELEVANCE: The management of severe aortic valve disease in adults younger than 65 years is complex, and there are numerous considerations with each management decision. While mechanical AVR and bioprosthetic AVR have historically been the standards of care, other options are emerging for selected patients but are not yet generalizable beyond specialized surgical centers. A detailed discussion by members of the multidisciplinary heart team and the patient is an integral part of the shared decision-making process.
引用
- Baman JR, Medhekar AN, Malaisrie SC, et al. Management Challenges in Patients Younger Than 65 Years With Severe Aortic Valve Disease: A Review. JAMA Cardiol. 2023. PMID: 36542365. doi:10.1001/jamacardio.2022.4770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。